Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue.
Am J Public Health
; 110(1): 61-64, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31725314
ABSTRACT
Clinical trials have demonstrated that preexposure prophylaxis (PrEP) protects against HIV infection; yet, even with its approval by the Food and Drug Administration (FDA) in 2012, less than 10% of eligible users in the United States are currently taking PrEP.While there are multiple factors that influence PrEP uptake and pose barriers to PrEP implementation, here we focus on PrEP's cost in the United States, which, at the current list price of $2000 per month and with high levels of cost sharing, can leave insured users with more than $1000 in out-of-pocket costs every year. We discuss how patient deductibles, monthly premiums, copayments, and coinsurance vary widely and may increase the financial burden. Although drug payment-assistance programs have made PrEP more affordable to uninsured and underinsured users, lack of insurance is a barrier to PrEP accessibility. The FDA approved a generic version in 2017; however, that version has not been distributed to US consumers and may not be more affordable.As other countries begin implementing PrEP programs, the extent of PrEP's availability as a tool in the global fight against HIV remains to be seen.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
/
Cobertura do Seguro
/
Profilaxia Pré-Exposição
/
Seguro de Serviços Farmacêuticos
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Am J Public Health
Ano de publicação:
2020
Tipo de documento:
Article